MX2011008763A - Peptidos foxm1 y vacunas que contienen los mismos. - Google Patents
Peptidos foxm1 y vacunas que contienen los mismos.Info
- Publication number
- MX2011008763A MX2011008763A MX2011008763A MX2011008763A MX2011008763A MX 2011008763 A MX2011008763 A MX 2011008763A MX 2011008763 A MX2011008763 A MX 2011008763A MX 2011008763 A MX2011008763 A MX 2011008763A MX 2011008763 A MX2011008763 A MX 2011008763A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- nucleic acids
- present
- same
- fragments
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 101150034834 Foxm1 gene Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 238000007792 addition Methods 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona péptidos aislados que tienen la secuencia de aminoácido de la SEC ID NO: 34 o fragmentos de la misma, que enlazan a antígenos HLA e inducen un linfocito citotóxico T (CTL). La presente invención proporciona además péptidos que incluyen una, dos o varias inserciones, substituciones o adiciones de aminoácidos a los péptidos o fragmentos antes mencionados, aunque aún tienen capacidad de inducción de célula citotóxica T. Se proporcionan además ácidos nucleicos que codifican cualesquiera de los péptidos antes mencionados así como substancias o composiciones farmacéuticas que incluyen cualesquiera de los péptidos o ácidos nucleicos antes mencionados. Los péptidos, ácidos nucleicos, substancias o composiciones farmacéuticas de la presente invención, se pueden utilizar para tratar cáncer o tumor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15340809P | 2009-02-18 | 2009-02-18 | |
PCT/JP2010/001005 WO2010095428A1 (en) | 2009-02-18 | 2010-02-17 | Foxm1 peptides and vaccines containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011008763A true MX2011008763A (es) | 2011-09-09 |
Family
ID=42633716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011008763A MX2011008763A (es) | 2009-02-18 | 2010-02-17 | Peptidos foxm1 y vacunas que contienen los mismos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US8617562B2 (es) |
EP (1) | EP2408912B1 (es) |
JP (1) | JP5728717B2 (es) |
KR (1) | KR101713586B1 (es) |
CN (1) | CN102405285B (es) |
BR (1) | BRPI1008887A2 (es) |
CA (1) | CA2752560C (es) |
DK (1) | DK2408912T3 (es) |
ES (1) | ES2618896T3 (es) |
IL (1) | IL214435A0 (es) |
MX (1) | MX2011008763A (es) |
RU (1) | RU2560431C2 (es) |
SG (1) | SG173751A1 (es) |
TW (1) | TWI469791B (es) |
WO (1) | WO2010095428A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010002002A (es) | 2007-08-20 | 2010-03-11 | Oncotherapy Science Inc | Peptido foxm1 y agente medicinal que lo contiene. |
SG11201405578TA (en) | 2012-03-09 | 2014-11-27 | Oncotherapy Science Inc | Pharmaceutical composition containing peptide |
GB201410686D0 (en) * | 2014-06-16 | 2014-07-30 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
BR112018005581A2 (pt) * | 2015-10-08 | 2018-10-16 | Oncotherapy Science, Inc. | peptídeo derivado de foxm1 e vacina incluindo o mesmo |
CN105524159B (zh) * | 2015-11-16 | 2021-04-09 | 西南交通大学 | 具有癌细胞选择性杀伤和迁移抑制作用的多肽分子与用途 |
CN105999227B (zh) * | 2016-08-12 | 2019-08-06 | 湖南大学 | FOXM1蛋白氮端(1-234 aa)的表达及其用途 |
JP2020503840A (ja) | 2016-10-07 | 2020-02-06 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Hla拘束性vgll1ペプチドおよびその使用 |
AU2018346765A1 (en) * | 2017-10-06 | 2020-04-16 | Oncotherapy Science, Inc. | Screening of T lymphocytes for cancer-specific antigens |
CN109055327B (zh) * | 2018-07-23 | 2021-04-06 | 浙江工业大学 | 醛酮还原酶突变体及其应用 |
CN114591400B (zh) * | 2022-03-29 | 2022-10-21 | 西南交通大学 | 一组靶向FoxM1-DBD多肽及其应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
US20030198642A1 (en) | 1995-08-03 | 2003-10-23 | Johannes J. Geuze | Cell derived antigen presenting vesicles |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
EP0960204A4 (en) | 1996-07-26 | 2002-01-23 | Sloan Kettering Inst Cancer | METHODS AND REAGENTS FOR GENETIC IMMUNIZATION |
US5861278A (en) | 1996-11-01 | 1999-01-19 | Genetics Institute, Inc. | HNF3δ compositions |
EP0846761A1 (en) | 1996-12-09 | 1998-06-10 | Introgene B.V. | A novel transcription factor expressed in cycling cells, nucleic acid molecules encoding said transcription factor and its promoter region and uses thereof |
FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
ATE375362T1 (de) | 1998-06-25 | 2007-10-15 | Kyogo Itoh | Von cyclophilin b abstammende tumorantigen- peptide |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7317140B2 (en) | 2001-06-04 | 2008-01-08 | Basf Plant Science Gmbh | Sugar and lipid metabolism regulators in plants II |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
EP1462456A4 (en) | 2001-12-10 | 2005-09-21 | Greenpeptide Co Ltd | TUMOR ANTIGENS |
AU2003272247A1 (en) * | 2002-08-28 | 2004-03-19 | The Board Of Trustees Of The University Of Illinois | Methods of treating age-related defects and diseases |
CA2500472A1 (en) * | 2002-09-30 | 2004-04-15 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human pancreatic cancers |
TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
WO2005090991A1 (en) | 2004-03-24 | 2005-09-29 | Oncotherapy Science, Inc. | Adam8 as tumor marker and therapeutic target for non-small cell lung cancer |
US20050260639A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
EP1615658A1 (en) | 2003-03-25 | 2006-01-18 | The Board Of Trustees Of The University Of Illinois | Inhibition of tumor cell proliferation by foxm1b inhibitors |
WO2005029067A2 (en) | 2003-09-24 | 2005-03-31 | Oncotherapy Science, Inc. | Method of diagnosing breast cancer |
CA2547635C (en) | 2003-12-12 | 2016-02-09 | Jeffrey Schlom | A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
US7655402B2 (en) | 2004-02-06 | 2010-02-02 | Wyeth Llc | Diagnoses and therapeutics for cancer |
ATE496142T1 (de) | 2004-03-23 | 2011-02-15 | Oncotherapy Science Inc | Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs |
CA2580412A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
JP2006141208A (ja) | 2004-11-16 | 2006-06-08 | Univ Of Tokushima | 多発性骨髄腫、白血病、悪性リンパ腫、肺癌等の免疫療法剤 |
EP2295601A1 (en) | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
EP2298895A1 (en) | 2005-07-27 | 2011-03-23 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
EP2311986B1 (en) | 2005-07-27 | 2015-04-15 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | T細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
EP1806413A1 (en) * | 2006-01-06 | 2007-07-11 | Oligene GmbH | An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer |
US20090311685A1 (en) | 2006-04-20 | 2009-12-17 | Oncotherapy Science, Inc | NMU-GHSR1b/NTSR1 oncogenic signaling pathway as a therapeutic target for lung cancer |
MX2010002002A (es) | 2007-08-20 | 2010-03-11 | Oncotherapy Science Inc | Peptido foxm1 y agente medicinal que lo contiene. |
BRPI0815578B8 (pt) | 2007-08-20 | 2021-05-25 | Oncotherapy Science Inc | peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina |
WO2010106770A1 (en) | 2009-03-18 | 2010-09-23 | Oncotherapy Science, Inc. | Neil3 peptides and vaccines including the same |
-
2010
- 2010-02-11 TW TW99104319A patent/TWI469791B/zh active
- 2010-02-17 RU RU2011138160/10A patent/RU2560431C2/ru not_active IP Right Cessation
- 2010-02-17 CN CN201080017145.2A patent/CN102405285B/zh active Active
- 2010-02-17 DK DK10743558.8T patent/DK2408912T3/en active
- 2010-02-17 MX MX2011008763A patent/MX2011008763A/es active IP Right Grant
- 2010-02-17 ES ES10743558.8T patent/ES2618896T3/es active Active
- 2010-02-17 WO PCT/JP2010/001005 patent/WO2010095428A1/en active Application Filing
- 2010-02-17 BR BRPI1008887A patent/BRPI1008887A2/pt not_active IP Right Cessation
- 2010-02-17 CA CA2752560A patent/CA2752560C/en not_active Expired - Fee Related
- 2010-02-17 JP JP2011535341A patent/JP5728717B2/ja active Active
- 2010-02-17 KR KR1020117021513A patent/KR101713586B1/ko active IP Right Grant
- 2010-02-17 EP EP10743558.8A patent/EP2408912B1/en active Active
- 2010-02-17 US US13/202,078 patent/US8617562B2/en active Active
- 2010-02-17 SG SG2011059441A patent/SG173751A1/en unknown
-
2011
- 2011-08-03 IL IL214435A patent/IL214435A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG173751A1 (en) | 2011-09-29 |
AU2010216980A1 (en) | 2011-08-25 |
RU2560431C2 (ru) | 2015-08-20 |
EP2408912B1 (en) | 2017-01-18 |
TWI469791B (zh) | 2015-01-21 |
BRPI1008887A2 (pt) | 2016-03-01 |
CN102405285A (zh) | 2012-04-04 |
JP5728717B2 (ja) | 2015-06-03 |
US20120156231A1 (en) | 2012-06-21 |
KR101713586B1 (ko) | 2017-03-08 |
TW201032821A (en) | 2010-09-16 |
DK2408912T3 (en) | 2017-03-20 |
ES2618896T3 (es) | 2017-06-22 |
JP2012517799A (ja) | 2012-08-09 |
CN102405285B (zh) | 2015-04-22 |
CA2752560A1 (en) | 2010-08-26 |
WO2010095428A1 (en) | 2010-08-26 |
EP2408912A4 (en) | 2013-04-17 |
CA2752560C (en) | 2017-01-24 |
RU2011138160A (ru) | 2013-03-27 |
KR20110117241A (ko) | 2011-10-26 |
US8617562B2 (en) | 2013-12-31 |
EP2408912A1 (en) | 2012-01-25 |
IL214435A0 (en) | 2011-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
NZ733168A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
EA202091251A2 (ru) | Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка | |
MY162737A (en) | 4-1bb binding molecules | |
HK1134507A1 (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
MX355759B (es) | Peptidos topk y vacunas que incluyen los mismos. | |
MX2012008657A (es) | Peptidos melk modificados y vacunas que contienen los mismos. | |
MX2012011668A (es) | Peptidos cdca5 y vacunas que incluyen los mismos. | |
MX2009007261A (es) | Vacuna de peptido foxp3. | |
MX2013014489A (es) | Peptidos sema5b y vacunas que incluyen los mismos. | |
MY166516A (en) | Tomm34 peptides and vaccines including the same | |
MX2011008917A (es) | Peptidos vangl1 y vacunas que incluyen los mismos. | |
EP3868778A3 (en) | Cdc45l peptides and vaccines including the same | |
NZ592461A (en) | Rab6kifl/kif20a epitope peptide and vaccines containing the same | |
MX2012006770A (es) | Peptidos tmem22 y vacunas que incluyen los mismos. | |
EA201291004A1 (ru) | Пептиды ect2 и включающие их вакцины | |
MX344579B (es) | Peptidos hjurp y vacunas que incluyen los mismos. | |
MX2013004417A (es) | Peptidos wdhd1 y vacunas que los incluyen. | |
BR112013009276A2 (pt) | peptídeos de c18orf54 e vacinas incluindo os mesmos | |
EP2370454A4 (en) | PEPTIDES WITH EPITAOPE WDRPUH AND VACCINES INCLUDING THEM | |
MX2012006376A (es) | Peptidos mybl2 y vacunas que los contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |